Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2013-03-26

FDA Approved: VPRIV — Supplemental Application (Takeda Pharmaceuticals America, Inc.)

View source ↗

Summary

The FDA approved a supplemental application for VPRIV (velaglucerase alfa) submitted by Takeda Pharmaceuticals America, Inc.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • VPRIV (VELAGLUCERASE ALFA)

Snippet

SUPPL AP for VPRIV (VELAGLUCERASE ALFA)